Month: March 2020

CAMBRIDGE, Mass., March 30, 2020 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported recent business highlights and full year 2019 financial results.“So far in 2020, we have made strides across all aspects of our business, and despite the many uncertainties we face today amid the COVID-19 pandemic, we remain committed to moving our programs forward for patients,” said John Evans, chief executive officer of Beam. “Following the successful completion of our initial public offering and the recent additions to our team, we have the resources needed to steadily advance a broad and deep portfolio of base editing programs addressing a wide range of disease areas and to invest in the science of base editing, illustrated by the recent...

NEWPORT BEACH, Calif., March 29, 2020 (GLOBE NEWSWIRE) — DPW Holdings, Inc. (NYSE American: DPW), a diversified holding company (“DPW,” or the “Company”), is providing an update relating to the impact that the coronavirus disease (“COVID-19”) is having on its business.Updates by business unit are as follows:DPW Holdings’ corporate headquarters, located in Newport Beach, CA, is closed and the headquarters staff is working remotely, based on the occupancy and social distancing orders from the State of California. The headquarters staff has tested the secure remote access systems and technology infrastructure to adjust working arrangements for its employees and believes it has adequate internal communications system and will remain operational with a remote staff. Coolisys Technologies Corp. (“Coolisys”), located in Fremont, CA, has...

Aspocomp Group Plc, Company Announcement, March 30, 2020 at 1:10 p.m.Notified details of the resulting situation on the date on which the threshold was crossed or reached:

Aspocomp Group Oyj, Pörssitiedote, 30.3.2020 klo 13.10Tiedot omistus- ja ääniosuudesta liputusrajan saavuttamisen tai rikkoutumisen jälkeen:

MELBOURNE, Australia, March 30, 2020 (GLOBE NEWSWIRE) — Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel biologic therapies to treat eye diseases, has completed patient dosing and all follow-up week 12 patient visits in the Company’s Phase 2a trial evaluating the safety and efficacy of OPT-302 administered in combination with aflibercept (Eylea®) for treatment of diabetic macular edema (DME).“We are extremely grateful to have reached this clinical milestone, particularly given the current challenges presented by the COVID-19 pandemic and restricted movements of patients globally. With all patients now having completed the treatment phase of the study, Opthea is now focused on data cleaning and preparation for data readout. A large proportion of the data cleaning activities have already been completed...

The Company is Accelerating its App Release to Provide Entertainment to Those Affected by COVID-19, Celebrity Music Artists and their Fans Following World Wide Concert Tour CancellationsCAMPBELL, CA, March 30, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – Friendable, Inc. (OTC: FDBL) today announces plans to accelerate its release of the Fan Pass Live Streaming Video application. The world has changed in recent weeks and Friendable is adapting its Fan Pass business model to allow Artists of all genres to share Live Video experiences, new music and event style entertainment that can be broadcast from the artists to their fans, directly from the Fan Pass mobile application. “Originally our goal for Fan Pass was driven by the desire to Live Stream the “Backstage Experience” of a concert event and open it up to all fans world-wide, but...